Innate Pharma (IPHA) Asset Utilization Ratio (2022 - 2025)

Innate Pharma (IPHA) has reported Asset Utilization Ratio for 4 consecutive years, with 0.97 the latest figure, recorded in Q4 2025.

• Quarterly Asset Utilization Ratio rose 17.9% year-over-year to 0.97 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.97 (up 17.9% YoY) and the FY2025 annual result came in at 0.1, down 26.28% from the prior year.
• Asset Utilization Ratio improved to 0.97 in Q4 2025 per IPHA's latest filing, from 0.82 in the prior quarter.
• Over the last five years, Asset Utilization Ratio for IPHA reached as high as 304.12 in Q2 2024 and fell as low as 0.06 in Q2 2022.
• A 4-year average of 146.89 and a median of 207.27 in 2022 frame the typical range for Asset Utilization Ratio.
• Annual changes were most pronounced in 2023 — Asset Utilization Ratio soared 392660.26% — and 2024, when it tumbled 99.69%.
• Year by year, Asset Utilization Ratio stood at 207.27 in 2022, then increased by 28.09% to 265.5 in 2023, then slumped by 99.69% to 0.82 in 2024, then grew by 17.9% to 0.97 in 2025.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.97, 0.82, and 304.12 for Q4 2025, Q4 2024, and Q2 2024 respectively.